Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.77 and traded as high as $2.01. Fortress Biotech shares last traded at $1.89, with a volume of 437,565 shares traded.
Fortress Biotech Stock Down 1.0%
The company has a debt-to-equity ratio of 1.74, a current ratio of 1.72 and a quick ratio of 1.55. The business has a 50-day moving average of $1.84 and a 200 day moving average of $1.77. The company has a market capitalization of $57.37 million, a PE ratio of -0.87 and a beta of 1.75.
Hedge Funds Weigh In On Fortress Biotech
Large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC lifted its holdings in shares of Fortress Biotech by 159.3% during the 1st quarter. Nantahala Capital Management LLC now owns 325,520 shares of the biopharmaceutical company's stock valued at $508,000 after acquiring an additional 200,000 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Fortress Biotech by 125.1% during the fourth quarter. Renaissance Technologies LLC now owns 175,800 shares of the biopharmaceutical company's stock worth $356,000 after buying an additional 97,712 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Fortress Biotech by 8.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,004,365 shares of the biopharmaceutical company's stock worth $1,567,000 after buying an additional 80,058 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Fortress Biotech by 30.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 239,594 shares of the biopharmaceutical company's stock valued at $485,000 after purchasing an additional 55,648 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in Fortress Biotech in the 4th quarter worth $109,000. Institutional investors and hedge funds own 96.51% of the company's stock.
Fortress Biotech Company Profile
(
Get Free Report)
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
See Also
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
